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Essentials
• Statins lower venous thromboembolism risk in general but have not been studied in cancer patients.
• We completed a randomized trial of rosuvastatin vs.
placebo among cancer patients on chemotherapy.
• Rosuvastatin did not significantly lower prothrombotic biomarkers including D-dimer.
• The role of statins in venous thrombosis prevention in cancer patients remains unknown.
Summary. Background: Statin therapy is associated with lower risk of venous thromboembolism (VTE) but has not been prospectively evaluated in patients with advanced cancer. Objectives: We determined if statin administration in this high-risk population reduces the risk of VTE, based on established and emerging biomarkers. Patients/Methods: This double-blind, crossover, randomized controlled trial among patients with advanced cancer receiving systemic therapy allocated participants to rosuvastatin 20 mg daily or placebo for 3-4 weeks prior to crossover to the alternative therapy, with a 3-5-week washout. D-dimer, Creactive protein (CRP), soluble (s)P-selectin, factor VIII (FVIII), thrombin generation and exploratory biomarkers focusing on endogenous thrombin potential, including tissue factor (TF), activated factor IX (FIXa) and activated factor XI (FXIa), were measured at the start and end of both treatment periods. The primary outcome was change in D-dimer with rosuvastatin compared with placebo. Results: Of 38 enrolled participants, 24 (63%) completed the study. Rosuvastatin did not cause statistically significant changes in D-dimer levels or any other biomarker. CRP levels decreased by 40%; 4.3 mg L À1 (95% confidence interval, À11.0 to +2.5 mg L À1 ) compared with placebo. In post-hoc analysis, participants who received rosuvastatin initially during their first line of treatment had a 13% decrease in D-dimer. Circulating TF, FIXa and FXIa were detected in 26%, 68% and 71% of cancer patients despite not being found in healthy individuals. Conclusions: Rosuvastatin did not cause favorable changes in biomarkers of VTE risk in advanced cancer patients receiving chemotherapy. The role of statin therapy as thromboprophylaxis in the cancer population remains uncertain.
Introduction
Patients with cancer are at high risk of developing venous thromboembolism (VTE) [1] . When VTE occurs in this population, prognosis is poor, with a 1-year survival of 12%, compared with 36% in the absence of VTE [2] , and a 25% 1-month mortality [3] . Prevention of VTE in patients with cancer is not routinely recommended, in part because of concern over an increase in bleeding risk with anticoagulant therapy. Options for prevention of VTE that do not impart a significant bleeding risk have the potential to be more broadly adopted and improve patient outcomes. Multiple studies [4] [5] [6] [7] [8] have confirmed the association between statin use and a lower risk of VTE. Statin use suppresses coagulation in experimental settings [9, 10] and is associated with a reduction in biomarkers of VTE risk [11] . Among statin users with cancer, a retrospective case-control study reported an 8% risk of VTE, compared with 21% in nonusers (odds ratio [OR], 0.33; 95% confidence interval [CI], 0.19, 0.59), after adjustment for other VTE risk factors [12] .
The impact of statin therapy on occurrence of VTE or biomarkers of VTE risk in cancer patients has not been studied prospectively.
In an effort to target patients at highest risk of VTE for thromboprophylaxis, a significant body of literature has identified biomarkers associated with higher risk of future VTE. One of the most robust markers of risk of thrombosis is D-dimer, a marker of coagulation activation. D-dimer is elevated in cancer patients, reflecting a hypercoagulable state [13] [14] [15] . In the Vienna Cancer & Thrombosis Study, patients with higher D-dimer and higher thrombin generation had a 6-month VTE incidence of 15.2%, compared with 5.0% for patients with lower levels of both biomarkers [16] . Conversely, D-dimer declines by over 40% with antithrombotic therapy in cancer patients [17] and is stable in individuals receiving anticancer treatment over time [18] . Thus, D-dimer meets all the criteria for a clinically useful VTE biomarker in cancer patients and served as our primary outcome.
Other relevant biomarkers are emerging in VTE risk prediction in both cancer and non-cancer patient populations. Higher C-reactive protein (CRP) was associated with risk of VTE in most but not all studies [19] [20] [21] [22] [23] [24] . Elevated sPselectin is a risk factor for recurrent VTE [25] and is also associated with risk of VTE in cancer patients [26] . Thrombin generation assays measure both the lag time and peak thrombin generation to quantify the composite effect of multiple risk factors for VTE [27] . Elevated peak thrombin generation is a risk factor for future VTE in healthy populations [28] and is inhibited by heparin [29] , suggesting this as a modifiable VTE biomarker. Elevated FVIIIc is independently associated with risk of VTE [30, 31] and is also elevated in cancer patients [32] . Tissue factor (TF) plays a role in cancer-derived coagulation alterations such as VTE [33, 34] . Activated factor XI (FXIa) and activated factor IX (FIXa) are also associated with hypercoagulability. These three proteins were detected and quantitated in patients with cardiovascular diseases, inflammation and trauma [35] [36] [37] [38] but have not been studied in patients with cancer and may represent novel procoagulant biomarkers in this high-risk population.
Given the growing evidence of a protective effect of statin therapy in reducing the risk of VTE in high-risk populations, and the emergence of multiple biomarkers for risk of VTE in cancer patients, we undertook a randomized crossover design clinical trial in patients with advanced malignancy to study the impact of rosuvastatin on the above-mentioned biomarkers of thrombosis.
Materials and methods

Design
We completed a double-blind randomized crossover study with each participant serving as their own control (Fig. 1) . Participants received rosuvastatin 20 mg orally once daily or matching placebo over a 3-4-week treatment period (TP) prior to a 3-5-week washout period then crossover to the alternative therapy.
Subjects
Inclusion criteria included adult patients (> 18 years of age with no upper age limit cut-off) at the University of Vermont Cancer Center with locally advanced or metastatic cancer prior to or during any systemic chemotherapy or targeted therapy. Individuals who had an estimated overall survival of greater than 6 months and anticipated duration of therapy of at least 3 months were enrolled. Exclusion criteria included current antithrombotic or statin therapy, systemic treatment with hormonal therapy alone, potential for concurrent medication interaction with rosuvastatin, thalidomide or lenalidomide-containing regimens, adjuvant therapy, known statin intolerance, transaminase levels above three times the upper limit of normal, GFR < 40 mL min À1 (MDRD) and Asian descent, because of slower rosuvastatin metabolism and concerns regarding toxicity at the 20-mg dose level [39] . All participants provided written informed consent. The protocol and consent forms were approved by the institutional review board at the University of Vermont and were registered under ClinicalTrials.gov (NCT01524653). A designated safety officer reviewed individual patient toxicity data every 3 months. Baseline testing consisting of a complete blood count, creatinine and liver profile was performed within 14 days of enrollment to verify eligibility and calculate a Khorana VTE risk score [40] .
Randomization
Participants were randomized in a double-blinded manner to one of two sequences (statin followed by placebo or placebo followed by statin) using random number generation by the SAS procedure PLAN (SAS Institute Inc., Cary, NC, USA; SAS v.9.3). Blocked randomization was used to ensure an approximately equal distribution of participants across study enrollment time. Randomization was implemented and concealed in our research pharmacy, which distributed the drug or matching placebo to participants. The allocation sequence was generated by our statistician (PC). Participating investigators in the Hematology-Oncology Clinic at the University of Vermont Medical Center enrolled participants, who were assigned to their group by the research pharmacy staff at a separate location. Participants, treating teams and all laboratory personnel involved in the protocol were blinded to group assignment.
Follow-up
Hepatic and renal function was subsequently monitored at the timed biomarker blood draws at the start and end of both TPs ( Fig. 1 ) to monitor the safety of prophylaxis. TP lengths were chosen at enrollment by the treating provider with intent to correspond to systemic therapy cycle durations so that biomarker draws occurred on the first day of a cycle of treatment administration prior to its administration. This controlled for possible acute effects of systemic therapy on biomarker levels by timing blood draws with day 1 of treatment cycles.
TP durations were consistent within a participant. For weekly and 3-week chemotherapy cycles, the TP length was 3 weeks. For 2 and 4-week cycles, the TP was 4 weeks. The washout period was 3-5 weeks to enable coordination of biomarker blood draws with day 1 of a given treatment cycle. Patients who developed VTE were removed from further study participation.
Biomarker measurement
Blood was drawn by atraumatic venipuncture. Samples were centrifuged at 3000 9 g for 10 min at 4°C. Following separation, plasma and serum were stored at -80C until analysis. At the end of the study, samples were analyzed at the University of Vermont Laboratory for Endogenous thrombin generation assay The following assay was used to measure exploratory biomarkers in this population, including plasma TF, FIXa and FXIa. Endogenous thrombin generation was measured as previously described [41, 42] and is based on the response of thrombin generation in contact-pathway-inhibited (CTI) plasma to the addition of inhibitory monoclonal antibodies to FXIa, FIXa and TF. Results were reported dichotomously (detectable or undetectable).
Blood draw #1
Blood draw #2
Blood draw #3
Blood draw #4 Pooled citrate platelet-poor plasma (PPP) was prepared in-house using 10 healthy donors [35] . Trypsin inhibitor from corn (CTI; prevents contact pathway initiation of coagulation) was prepared as previously described [43, 44] . Phospholipid vesicles (PCPS) composed of 25% dioleoylsn-glycero-3-phospho-L-serine and 75% 1,2-dioleoyl-snglycero-3-phosphocholine (both from Avanti Polar Lipids, Inc., Alabaster, AL, USA) were prepared as described previously [45] . Inhibitory monoclonal anti-TF (aTF-5; prevents binding of TF to FVIIa), anti-FXIa (aFXI-2; inhibits FIX activation by FXIa) and anti-FIXa (aFIX-91; inhibits FX activation by FIXa) antibodies were produced and characterized in-house [46] [47] [48] . The fluorogenic substrate used was benzyloxycarbonyl-GlyGly-Arg-7-amido-4methylcoumarin• HCl (Z-GGR-AMC) (Bachem, Torrance, CA, USA). TF, FIXa and FXIa activity in plasma was calculated from calibration curves developed with human FIXa, human FXIa or relipidated TF 1-263 [43] (all from Haematologic Technologies, Inc., Essex Junction, VT, USA). Human thrombin was produced in-house [49] . HEPES buffered saline (HBS) buffer was prepared using N-[2-hydroxyethyl]piperazine-NN-[2-ethanesulfonic acid] (HEPES) and NaCl (Fisher Scientific, Waltham, MA, USA) (HBS; 20 mM HEPES, 0.15 M NaCl, pH 7.4). CaCl 2 used was from Fisher Scientific. The thrombin generation assay was performed in untreated, polystyrene 96-well plates (Costar, Lowell, MA, USA). The plate reader used was the BioTek Synergy 4 and analysis was performed using the Gen5 plate reader software (BioTek, Winooski, VT, USA).
Statistical analysis
The primary outcome, defined as DD = DRosuvastinDPlacebo, was the change in D-dimer level with rosuvastatin therapy (DRosuvastin
Power calculations tested an alternative hypothesis of a 25% decrease in D-dimer levels with statin therapy. This threshold was chosen based on Vienna Cancer and Thrombosis Study results, in which D-dimer levels were 25% lower in patients with cancer who did not subsequently develop VTE compared with those who did [16] . Based on a standard deviation of 0.70 lg mL À1 for Ddimer in patients receiving chemotherapy [13, 16] , and assuming a 30% dropout rate, an accrual goal of 40 participants was planned. Data were presented as mean AE standard deviation (SD) or median with 25th and 75th percentiles as appropriate. Baseline characteristics were compared based on protocol completion status using Fisher's exact tests, Wilcoxon rank sum tests and log-transformed t-tests as appropriate. We first evaluated the distributions of each biomarker blind to treatment allocation and time-point to determine whether there were obvious analytic outliers that could obscure treatment effects. We did not identify such outlying values. All biomarker differences between the treatment and placebo periods were evaluated in those who completed the protocol using ANOVA testing for 2 9 2 crossover experiments with log-transformation when appropriate, and evaluation for period and treatment effects. Potential biomarker changes between periods were analyzed using D values, analogous to D-dimer calculations. A secondary analysis of participants on first versus subsequent line chemotherapy was performed by using linear regression with differences compared using an unpaired Student's ttest, and adjustment for Khorana score at baseline, age, gender and receipt of platinum-based chemotherapy. A two-sided P-value of 0.05 was considered statistically significant. All analyses were performed in Stata 14.1 (StataCorp 2015. Stata Statistical Software: Release 14. StataCorp LP, College Station, TX, USA
Results
Patient characteristics
Enrollment was completed from March 2012 to November 2013. Of the 38 participants enrolled, 14 withdrew, resulting in 24 participants completing the protocol. A total of 116 blood samples were collected. Five participants withdrew consent (one because of myalgias while taking placebo), three had VTE events, three were excluded as a result of pharmacy error (resulting in the study drug being given in the incorrect sequence), and three participants had rapidly progressive disease requiring withdrawal from anticancer therapy. Adverse reactions to rosuvastatin were rare. Three participants reported myalgias during the study but only one withdrew because of this symptom. No participants were withdrawn as a result of creatine kinase or transaminase elevations.
Study participants were all Caucasian, with a median age of 61 years ( Table 1) . The majority had advanced pancreatic cancer or lymphoma and were undergoing first-line chemotherapy. There was heterogeneity in the primary cancer site and chemotherapy regimen, with 25 different regimens among 38 participants. Based on the Khorana score, 52% of participants were at intermediate or high risk of developing a cancer-associated VTE.
Baseline biomarker assessment
The mean D-dimer level was elevated at twice the upper limit of normal (1.0 lg mL À1 ) at baseline. CRP and D-dimer levels were elevated at baseline in participants who completed therapy and in the entry cohort (Tables 2  and 3 ), whereas sP-selectin and peak thrombin generation were only elevated in the baseline cohort. Exploratory biomarkers focusing on endogenous thrombin potential, including TF, FIXa and FXIa, were aberrantly detected in 26%, 68% and 71% of patients, respectively, at baseline. Of these, there were correlations between baseline FXIa and FIXa levels (R = 0.37, P = 0.02) as well as FXIa and TF levels (R = 0.57, P < 0.001). No correlation between FIXa and TF was observed (R = 0.02, P = 0.91). There were no significant correlations between any of the three exploratory biomarkers and other biomarkers.
Impact of rosuvastatin on biomarkers of thrombosis Table 3 provides data on observed changes in mean biomarker levels, including the primary outcome of D-dimer. There was no significant change in D-dimer levels with rosuvastatin treatment compared with placebo. In contrast, CRP decreased by over 40% (4.3 mg L À1 ) with active treatment compared with placebo, but the decline was not statistically significant. Treatment effects were minor for sP-selectin, FVIIIc and peak thrombin generation. There was no evidence for period or sequence effects for any of the biomarkers. There were no significant changes in the number of participants who showed activity of TF, FIXa and FXIa before and after treatment with rosuvastatin. Among participants with detectable levels of TF, FIXa and FXIa, the mean levels of these biomarkers likewise showed no significant changes with rosuvastatin compared with placebo (data now shown).
In a secondary analysis using multivariable linear regression, there was a significant sequence by line of chemotherapy interaction (P = 0.04), although no sequence effect was seen with ANOVA. Participants receiving their first line of chemotherapy, and who were receiving rosuvastatin first, had a 13% decrease in D-dimer, whereas participants receiving their second to fifth line of chemotherapy, or who received rosuvastatin after placebo in the study, had a 12% increase in D-dimer (P = 0.09 for interaction). Participants receiving their first line of chemotherapy and who received rosuvastatin first, also had modestly greater declines in their CRP (54%) and sP-selectin (9%), although these declines were also not statistically significant. Adjustment for other baseline variables, including Khorana score, did not reveal any further significant biomarker associations.
Observed clinical events VTE events occurred in three of the 38 participants in the study. All three patients who developed a VTE had baseline CRP and D-dimer that were higher than the median values of study participants. Participants who developed a VTE had three of the four highest baseline peak thrombin generation levels. Two of the three participants who developed a VTE had an intermediate or high-risk Khorana score at baseline.
Discussion
In this randomized crossover trial focused on an advanced cancer patient population, no favorable effects Table 2 Baseline biomarker levels of study participants (n = 38) Standard biomarkers † Baseline level IR, interquartile range; SD, standard deviation. *Normal value = 0 (not detectable in blood draws from healthy volunteers). †Medians and interquartile ranges used for skewed distributions. were detected in any of the studied biomarkers of VTE risk when comparing rosuvastatin with placebo. The primary outcome of decline in D-dimer was not seen. Posthoc analysis suggested that participants who received rosuvastatin earlier in their treatment course with their first line of treatment, had a modest decrease in D-dimer.
Although there was a 40% decrement in mean CRP with rosuvastatin compared with placebo, this did not reach statistical significance. Circulating active coagulation factors were detected, including TF in a minority of trial participants and FIXa and FXIa in the majority. The presence of detectable levels of these biomarkers did not change significantly with rosuvastatin administration. VTE remains the second most common cause of death in patients with cancer, second only to cancer itself [50] . Biomarkers, such as markers of inflammation or the endogenous activation of coagulation, correlate with risk of VTE, but none are currently used in clinical decision making to provide VTE prophylaxis. Although statins decrease inflammatory and coagulation biomarkers in healthy individuals [5] [6] [7] [8] , we did not detect similar effects in this cohort of cancer patients. The reason for this discordance is likely to be multifactorial, but it is important to note that enrollment was not restricted to the first cycle of a line of therapy based on prior evidence of D-dimer stability during chemotherapy [13] . With the propensity to develop VTE varying with type of cancer [51] , stage [52] and time period after diagnosis [1] , it is possible that the ability of statin therapy to mitigate thrombotic risk may vary by the same or other factors.
Although the net change in CRP did not meet statistical significance, the magnitude of decline with statin therapy compared with placebo points to a potentially meaningful decrease in inflammation with statin therapy as would be expected. In the JUPITER trial, changes in CRP levels while on statin therapy were predictive of vascular events, but not specifically VTE [53] . The value of changes in CRP as a predictive dynamic biomarker for risk of VTE in patients receiving statin therapy remains unclear at this time.
This study had several limitations. We included patients with advanced cancer, but patients were not selected based on risk of VTE and 47% of participants had low-risk Khorana scores. Only 63% of enrolled participants were able to complete follow-up, and the study population was heterogeneous for site of primary cancer and line of therapy, which may have obscured positive findings in a subset of patients. Additionally, despite the efficiency afforded by a crossover design, we cannot rule out period effects given our small sample size, and that post-hoc analysis results showed a decline in D-dimer in the patient subset on firstline therapy and randomized to rosuvastatin first. These findings could have clinical relevance because first-line chemotherapy is considered a high-risk time for VTE but require replication in a larger study. Like any study of patients with advanced cancer, despite prior work [13] , variation of all studied biomarkers is expected to be higher than in healthier populations, potentially limiting the ability to detect clinically relevant changes in biomarkers. Finally, treatment duration in this trial might have been inadequate. The intent of a 3-4-week duration of rosuvastatin or placebo treatment was to minimize the burden of additional blood draws on participants and minimize loss to follow-up. The PROVE IT TIMI-22 study showed that statin therapy caused substantial declines in CRP within 30 days [54] . However, CRP was lowered even further after 4 months of therapy, so the duration of treatment in our trial may have been insufficient to detect changes. CRP, C-reactive protein; sP-selectin, soluble P-selectin; TF, tissue factor; FXIa, activated factor XI; FIXa, activated factor IX; 95% CI, 95% confidence interval. *TF, FIXa and FXIa levels are presented dichotomously (detectable or undetectable). The net change (representing the number of patients with detectable levels in the active treatment arm controlled for the change in the placebo arm) was not statistically significant for TF, FIXa or FXIa. *P values obtained using natural log transformed data for D-dimer, CRP, sP-selectin and FVIII Ag.
Based on biomarker analysis, our study findings suggest that statins may have a limited role in reducing the risk of thrombosis in patients with advanced cancer. Our results suggest that additional studies focused on enrolling patients prior to start of chemotherapy may provide further insights. In addition, our exploratory biomarkers suggest that an additional procoagulant mechanism, endogenous activated and circulating tissue factor, FIXa and FXIa, is present in patients with advanced malignancy and should be explored further in broader cancer patient populations. 
